Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment

作者：Litvan Irene^*; Kieburtz Karl; Troster Alexander I; Aarsland Dag

来源：Movement Disorders, 2018, 33(4): 520-527.

DOI：10.1002/mds.27345

• mild cognitive impairment
• Parkinson disease
• clinical trials
• pharmacologic
• nonpharmacologic

Treatments to slow the progression of cognitive dysfunction to dementia and improve the quality of life of persons with Parkinson's disease (PD) are desperately needed. Because PD mild cognitive impairment is considered a transitional stage before dementia, it opens a window to timely intervention. This article critically reviews the strengths and challenges of pharmacologic and nonpharmacologic clinical therapeutic trials in PD mild cognitive impairment conducted during the past 5 years, including ongoing trials. Relatively few high-quality trials have been conducted, and some important factors in designing future clinical trials are discussed.

• 出版日期2018-4